1400 Coleman Avenue, Suite D27, Santa Clara, CA 95050, USA
Luxena Pharmaceuticals, Inc. © ALL RIGHTS RESERVED
Luxena Pharmaceuticals, Inc.
LPI-1503 is to prevent and treat nausea and vomiting induced by chemotherapy, radiotherapy or surgery. The benefits of LPI-1503 includes fast-onset, non-invasive, convenience, enhanced safety and efficacy.
Development Status
* Completed formulation development with excellent stability data.
* Finished animal pharmacokinetics (PK) studies in rats and dogs.
* Secured a simplified 505(b)(2) development pathway for LPI-1503.
# Received positive responses from FDA through a Type B pre-IND meeting.
# Established chains of GXP CROs to execute the plans agreed by FDA.
* Granted by FDA an orphan drug designation for one of its indications.